Gapping up
In reaction to strong earnings/guidance: MEET +23.6%, LEN +4.1%
M&A news: MCGC +0.9% (received a revised acquisition proposal from HC2 Holdings (HCHC)), MR +0.8% (forms special committee to evaluate previously announced $30/share 'Going Private' proposal)
Other news: CPXX +13.4% (announces positive induction response results from Phase 3 Study of CPX-351 in patients with high-risk (secondary) acute Myeloid Leukemia), ARTX +13.2% (announces $8.7 mln in New Orders), NVGN +8.3% (cytotoxic chemotherapy drug, Anisina, has been fast-tracked by the Company to be ready to come into clinics), BOX +6% (Box and IBM (IBM) announce partnership to collaborate in cloud-based services ), NKTR +5% (to replace CASY in the S&P SmallCap 600), SMI +4.7% (SMI, Huawei, and QCOM form JV), CREG +4.5% (enters into a repurchase agreement for the waste heat power generation, with Sinosteel Group Jilin Ferroalloys), KITE +4.4% (CEO discusses co's immunotherapy treatment on CNBC), MELA +3.8% (modestly ticking higher after yesterday's weakness), TKAI +3.3% (initiates a Phase 3 clinical trial of Galeterone, in men with metastatic castration-resistant prostate cancer), NFLX +2.9% (announces seven-for-one stock split), ORAN +2.6% (announced the expansion and availability in Asia Pacific), WATT +2.3% (following yesterday's ~25% move higher), CNIT +1.8% (reports a strategic agreement with the Linyi municipal government, to implement its the 'CNIT Internet + Smart Linyi' project), CASY +1% (to replace AOL int he S&P MidCap 400), VNDA +0.8% (reports positive results from the long-term maintenance REPRIEVE), PSTI +0.8% (granted Australian patent for 3D Cell Expansion Technology & use of PLX cells in broad range of indications)
Analyst comments: CPRX +8.5% (initiated with a Buy at MLV & Co; $14 tgt; also - reports top-line results in a proof-of-concept trial of Vigabatrin), EA +2.1% (upgraded to Buy from Hold at Jefferies), VMW +1.8% (added to Conviction Buy List at Goldman), AMAT +1.7% (added to Conviction Buy List at Goldman), F +1.6% (upgraded to Buy from Neutral at Goldman),RDS.A +1.4% (upgraded to Buy from Hold at Deutsche Bank), CCL +1.1% (target raised to $60 at Stifel), BHP +0.8% (upgraded to Neutral from Underperform at Credit Suisse), AVGO +0.8% (initiated with a Buy at Argus; tgt $163), RCL +0.7% (upgraded to Buy from Neutral at Goldman), CORR +0.7% (upgraded to Outperform at RBC Capital Mkts), TERP +0.7% (added to Analyst Focus List at JP Morgan
)
In reaction to strong earnings/guidance: MEET +23.6%, LEN +4.1%
M&A news: MCGC +0.9% (received a revised acquisition proposal from HC2 Holdings (HCHC)), MR +0.8% (forms special committee to evaluate previously announced $30/share 'Going Private' proposal)
Other news: CPXX +13.4% (announces positive induction response results from Phase 3 Study of CPX-351 in patients with high-risk (secondary) acute Myeloid Leukemia), ARTX +13.2% (announces $8.7 mln in New Orders), NVGN +8.3% (cytotoxic chemotherapy drug, Anisina, has been fast-tracked by the Company to be ready to come into clinics), BOX +6% (Box and IBM (IBM) announce partnership to collaborate in cloud-based services ), NKTR +5% (to replace CASY in the S&P SmallCap 600), SMI +4.7% (SMI, Huawei, and QCOM form JV), CREG +4.5% (enters into a repurchase agreement for the waste heat power generation, with Sinosteel Group Jilin Ferroalloys), KITE +4.4% (CEO discusses co's immunotherapy treatment on CNBC), MELA +3.8% (modestly ticking higher after yesterday's weakness), TKAI +3.3% (initiates a Phase 3 clinical trial of Galeterone, in men with metastatic castration-resistant prostate cancer), NFLX +2.9% (announces seven-for-one stock split), ORAN +2.6% (announced the expansion and availability in Asia Pacific), WATT +2.3% (following yesterday's ~25% move higher), CNIT +1.8% (reports a strategic agreement with the Linyi municipal government, to implement its the 'CNIT Internet + Smart Linyi' project), CASY +1% (to replace AOL int he S&P MidCap 400), VNDA +0.8% (reports positive results from the long-term maintenance REPRIEVE), PSTI +0.8% (granted Australian patent for 3D Cell Expansion Technology & use of PLX cells in broad range of indications)
Analyst comments: CPRX +8.5% (initiated with a Buy at MLV & Co; $14 tgt; also - reports top-line results in a proof-of-concept trial of Vigabatrin), EA +2.1% (upgraded to Buy from Hold at Jefferies), VMW +1.8% (added to Conviction Buy List at Goldman), AMAT +1.7% (added to Conviction Buy List at Goldman), F +1.6% (upgraded to Buy from Neutral at Goldman),RDS.A +1.4% (upgraded to Buy from Hold at Deutsche Bank), CCL +1.1% (target raised to $60 at Stifel), BHP +0.8% (upgraded to Neutral from Underperform at Credit Suisse), AVGO +0.8% (initiated with a Buy at Argus; tgt $163), RCL +0.7% (upgraded to Buy from Neutral at Goldman), CORR +0.7% (upgraded to Outperform at RBC Capital Mkts), TERP +0.7% (added to Analyst Focus List at JP Morgan
)